First monkeypox deaths outside Africa recorded
Monkeypox has claimed the first lives outside Africa – one in Brazil and another two in Spain – although the World Health organization (WHO) has […]
Monkeypox has claimed the first lives outside Africa – one in Brazil and another two in Spain – although the World Health organization (WHO) has […]
Some patients with COVID-19 will be able to get easier access to Pfizer’s oral antiviral therapy Paxlovid, after the FDA ruled that pharmacists would be […]
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking […]
The World Health organisation’s latest assessment of the monkeypox outbreak is that it poses a moderate threat to public health, as cases of the infection […]
The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan Africa, with cases rising above the 100-mark […]
An antiviral that Enanta Pharmaceuticals is developing for respiratory syncytial virus infection failed to beat a placebo in its first Phase 2 test. But the […]
Chimerix is selling global rights to smallpox drug Tembexa, the biotech’s only FDA-approved product, as a way to fund clinical development of a therapy in […]
Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was […]
We may feature your response in the Coronavirus Briefing newsletter.
Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). […]
UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people […]
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives […]
The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug. […]
In April 2020, I wrote a blog post entitled “Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development,” where I described […]
There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an […]
Pfizer’s Paxlovid has become the first oral antiviral for COVID-19 to be authorised for emergency use by the FDA, as the US braces itself for […]
The EMA’s human medicines committee has said that EU member states can start to offer Pfizer’s oral antiviral Paxlovid as a treatment for people with […]
Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the […]
Telehealth, diagnostics and pharmacy business Truepill will launch a new virtual care platform in the coming weeks that it says will provide “end-to-end” care for […]
An FDA advisory committee voted by 13 to 10 to recommend emergency-use authorisation for Merck & Co and Ridgeback’s oral antiviral molnupiravir for mild-to-moderate COVID-19, […]
Merck & Co has reported new data with its oral antiviral molnupiravir that suggests it is not as effective against COVID-19 as originally hoped. An […]
Takeda has scored the first-ever FDA approval of a treatment for refractory cytomegalovirus (CMV) infections in organ transplant patients, which can lead to an increased […]
Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, […]
Already making big profits from its COVID-19 vaccine, Pfizer looks set to bolt on another big revenue stream with its oral antiviral drug Paxlovid after […]
Armed with impressive new data for its oral antiviral Paxlovid, Pfizer has filed for emergency use authorisation as a COVID-19 treatment in the US – […]
The US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics’ oral antiviral molnupiravir for COVID-19, adding to an […]
An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the […]
Merck & Co and Ridgeback’s oral antiviral molnupiravir has been approved in its first market – the UK – as a treatment for people with […]
A generic pill has been shown to reduce hospitalisation rates in high-risk patients with early COVID-19, potentially offering a low-cost alternative to oral antivirals from […]
Merck & Co has signed a licensing deal with the UN-backed Medicines Patent Pool (MPP) that could pave the way for generic companies to manufacture […]
The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics’ much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults. […]
As expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral molnupiravir, aiming to protect people with mild […]
Takeda is closing on a first FDA approval in the treatment of refractory cytomegalovirus (CMV) infections in organ transplant patients, after agency advisors voted unanimously […]
Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations […]
The Bill & Melinda Gates Foundation must have liked what it saw in an initial collaboration with Exscientia to find new antivirals for COVID-19 and […]
Health Canada has started a rolling review of Merck & Co’s molnupiravir, an oral antiviral therapy treatment for COVID-19 partnered with Ridgeback Biotherapeutics. The Canadian […]
The Biden Administration has said it will allocate $3 billion of its pandemic rescue plan to the development of a new generation of antiviral therapies […]
The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it […]
UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled therapy for COVID-19 that could be ready […]
Shots: Tetra and Targeted Pharmaceuticals collaborated with George Mason University NCBID to examine the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications The […]
The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed […]
Copyright © 2024 | WordPress Theme by MH Themes